Obseva (NASDAQ:OBSV) has been assigned a $44.00 price target by HC Wainwright in a research note issued to investors on Wednesday, June 5th, TipRanks reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 289.04% from the stock’s previous close.
Several other brokerages also recently issued reports on OBSV. Wedbush set a $38.00 price objective on shares of Obseva and gave the stock a “buy” rating in a research report on Friday, May 10th. Zacks Investment Research raised shares of Obseva from a “sell” rating to a “hold” rating in a research report on Saturday, June 1st. Finally, ValuEngine raised shares of Obseva from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $28.83.
NASDAQ OBSV traded up $0.51 on Wednesday, reaching $11.31. The company’s stock had a trading volume of 52,400 shares, compared to its average volume of 48,399. Obseva has a 52 week low of $9.73 and a 52 week high of $19.40. The company’s 50-day moving average price is $11.93. The stock has a market capitalization of $478.42 million, a price-to-earnings ratio of -5.92 and a beta of 1.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.73 and a current ratio of 6.73.
Institutional investors have recently added to or reduced their stakes in the stock. Gables Capital Management Inc. acquired a new position in shares of Obseva during the 4th quarter valued at $25,000. Barclays PLC grew its position in Obseva by 331.1% during the fourth quarter. Barclays PLC now owns 10,118 shares of the company’s stock valued at $128,000 after buying an additional 7,771 shares during the period. Geode Capital Management LLC bought a new position in Obseva during the fourth quarter valued at about $159,000. Jane Street Group LLC bought a new position in Obseva during the fourth quarter valued at about $218,000. Finally, Wedbush Securities Inc. bought a new position in Obseva during the fourth quarter valued at about $264,000. Institutional investors own 63.58% of the company’s stock.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: Return On Assets
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.